Viridian Therapeutics, Inc. (NASDAQ:VRDN) Sees Significant Growth in Short Interest
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Sees Significant Growth in Short Interest
Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Rating) was the recipient of a significant increase in short interest in the month of November. As of November 15th, there was short interest totalling 2,830,000 shares, an increase of 25.2% from the October 31st total of 2,260,000 shares. Based on an average daily trading volume, of 475,100 shares, the days-to-cover ratio is currently 6.0 days.
维里迪安治疗公司(纳斯达克代码:VRDN-GET评级)是11月份空头股数使用量大幅增加的接受者。截至11月15日,空头股数共有2,830,000股,较10月31日的2,260,000股增加25.2%。以日均成交量475,100股计算,目前天数与回补比率为6.0天。
Analyst Ratings Changes
分析师评级发生变化
Several analysts have issued reports on the company. Evercore ISI boosted their target price on Viridian Therapeutics from $40.00 to $50.00 in a research note on Monday, August 15th. SVB Leerink boosted their price objective on Viridian Therapeutics from $32.00 to $40.00 and gave the company an "outperform" rating in a research note on Monday, August 15th. LADENBURG THALM/SH SH upped their price target on Viridian Therapeutics from $33.00 to $40.00 and gave the company a "buy" rating in a research report on Tuesday, August 16th. B. Riley raised their price objective on shares of Viridian Therapeutics from $25.00 to $40.00 in a research report on Tuesday, August 16th. Finally, HC Wainwright began coverage on shares of Viridian Therapeutics in a research report on Thursday. They issued a "buy" rating and a $35.00 price objective for the company. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $42.00.
几位分析师已经发布了关于该公司的报告。Evercore ISI在8月15日星期一的一份研究报告中将他们对Viridian治疗公司的目标价从40.00美元上调至50.00美元。SVB Leerink在8月15日星期一的一份研究报告中将他们对Viridian Treeutics的目标价从32.00美元上调至40.00美元,并给予该公司“跑赢大盘”的评级。8月16日,星期二,拉登堡THALM/SH SH在一份研究报告中将他们对Viridian治疗公司的目标价从33.00美元上调至40.00美元,并给予该公司“买入”评级。B.Riley在8月16日星期二的一份研究报告中将Viridian治疗公司的股票目标价从25.00美元上调至40.00美元。最后,HC Wainwright在周四的一份研究报告中开始报道Viridian治疗公司的股票。他们对该公司的评级为“买入”,目标价为35.00美元。根据MarketBeat的数据,五位投资分析师对该股的评级为买入,目前该股的平均评级为“买入”,平均目标价为42.00美元。
Insider Buying and Selling at Viridian Therapeutics
Viridian Treeutics的内幕买卖
In other Viridian Therapeutics news, General Counsel Lara Meisner sold 8,125 shares of the business's stock in a transaction on Tuesday, November 15th. The stock was sold at an average price of $22.05, for a total value of $179,156.25. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 4.48% of the company's stock.
在其他Viridian治疗公司的消息中,总法律顾问Lara Meisner在11月15日星期二的一笔交易中出售了8,125股该公司的股票。这只股票的平均售价为22.05美元,总价值为179,156.25美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可以通过此超链接。公司内部人士持有该公司4.48%的股份。
Institutional Investors Weigh In On Viridian Therapeutics
机构投资者看好Viridian Treeutics
Viridian Therapeutics Price Performance
Viridian治疗药物的价格表现
Shares of VRDN stock traded up $0.72 during trading hours on Thursday, reaching $25.99. The stock had a trading volume of 9,409 shares, compared to its average volume of 430,802. Viridian Therapeutics has a 12 month low of $9.47 and a 12 month high of $27.08. The firm has a market capitalization of $739.68 million, a PE ratio of -5.99 and a beta of 0.84. The company has a current ratio of 17.35, a quick ratio of 17.35 and a debt-to-equity ratio of 0.02. The stock's fifty day simple moving average is $20.69 and its 200 day simple moving average is $17.33.
在周四的交易中,VRDN股票的交易价格上涨了0.72美元,达到25.99美元。该股成交量为9,409股,而其平均成交量为430,802股。Viridian Treeutics的12个月低点为9.47美元,12个月高位为27.08美元。该公司市值为7.3968亿美元,市盈率为-5.99,贝塔系数为0.84。该公司的流动比率为17.35,速动比率为17.35,债务权益比率为0.02。该股的50日简单移动均线为20.69美元,200日简单移动均线为17.33美元。
About Viridian Therapeutics
关于维里迪安治疗学
(Get Rating)
(获取评级)
Viridian Therapeutics, Inc, a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED.
Viridian治疗公司是一家生物技术公司,为患有严重疾病的患者开发治疗方法。它开发了人源化的抗IGF-1R抗体VRDN-001,用于治疗甲状腺眼病(TED)的1/2期临床试验;VRDN-002,用于治疗甲状腺眼病的IGF-1R抗体;以及VRDN-003,用于治疗TED的IGF-1R治疗性抗体。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Viridian Therapeutics (VRDN)
- Are the Short Sellers Still Right About Mullen Automotive stock?
- La-Z-Boy Reclines To More Comfortable Levels
- Is The Recovery Rally Here For SoFi?
- Is Apple Going To Rally Into Year End?
- Will Easing Of Covid Rules Slash Risk For Chinese EV Maker NIO?
- 免费获取StockNews.com关于病毒治疗(VRDN)的研究报告
- 卖空者对马伦汽车股票的看法仍然正确吗?
- La-Z-Boy倾斜到更舒适的水平
- 复苏集会是为SoFi而来的吗?
- 苹果会在年底前大涨吗?
- 放宽Covid规则会降低中国电动汽车制造商蔚来的风险吗?
Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Viridian Treateutics Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Viridian Treeutics和相关公司的最新新闻和分析师评级的每日简要摘要。